Recent Articles
Most Popular
China Stocks
Consumer Stocks
Energy Stocks
ETFs & Mutual Funds
Global Investing
Gold & Materials Stocks
Income Investing
Industrial Stocks
Healthcare & Biotech
Technology Stocks
| Changewave speculates on Alzheimer's |
|
"The company's Alzheimer's disease drug drug, called PBT-2, is in Phase II trials in Sweden and aims at limiting the interaction between naturally occurring metals in the body (specifically in the area of the brain) and beta amyloid proteins that are at the heart of the plaques thought to be the cause of Alzheimer's disease. "Prana has its place in our highly speculative portfolio because most other science aimed at limiting the creation of plaques has failed big time by taking a totally wrong approach discredited during the past three years. "Prana is indeed a long shot. It's one of those biotechs we sometimes love and sometimes hate. Its current trials will be completed in December and if they show efficacy the stock is worth $7-$10. "If and when PRAN finds a partner to fund phase III trials, the stock is maybe worth $12-$20. Of course, there is the downside possibility that the drug fails and the stock is then worth 50 cents. "The current price is $3-plus, and it's worth purchasing if you have some Vegas money that's burning a hole in your pocket -- please, not the mortgage money or any other funds you'd miss." |
As a speculation on an Alzheimer's drug, Michael Shulman owns Newsletter News & Deals
Get our Free Daily Digest
| Dividend Still Don't Lie |
Dividends Don't Lie -- by IQ Trends founder Geraldine Weiss -- is one of the all-time great investment books. Now, editor Kelley Wright is following up this classic with Dividend Still Don't Lie, which can be pre-ordered at a significant discount. |
| Rhino Stocks: Free webinar |
| Jonas Elmerraji, editor of the Rhino Stock Report has released a 29-minute webinar, Planning Your Entries and Exits With Technical Analysis. It is available free with site registration. Click here. |
| Free report from Ken Kam |
Ken Kam of Marketocracy has just published a free report outlining his 2010 strategy. To view "The New Rules for Investing", click here. |
| Meet Gordon Pape in Toronto |
Gordon Pape, editor of The Internet Walth Builder, will be speaking at the Fairmont Royal York Hotel Toronto on February 13 and 14. Click here for details. |
| Keith Fitz-Gerald: Fiscal Hangover |
Get a $10 discount on Keith's new book on global investing -- Fiscal Hangover. Click here. |
| Delfeld: Red, White & Bold |
Global expert Carl Delfeld's new book -- Red, White & Bold -- is now available. |
| Meet the KCI editors |
Join Roger Conrad, Gregg Early, Elliott Gue, Yiannis Mostrous, and Benjamin Shepherd at the Hotel del Coronado for the 2010 KCI Wealth Society Member Summit. Call 1-800-832-2330 (between 9:00 a.m. and 5:00 p.m. EST Monday through Friday) or go to www.InvestingSummit.com. |
| Toby Smith goes "green" |
Toby Smith, editor of ChangeWave Investing, has just published his new book on investing in green technology -- Billion Dollar Green. |
| An expert's guide to China |
Check out Becoming Your Own China Stock Guru, a new book by China expert Jim Trippon -- editor of The China Stock Digest. To order the book, click here. |
| EconoPower: New from Skousen |
Mark Skousen's latest book, “EconoPower: How a New Generation of Economists is Transforming the World” (Wiley & Sons), is available for $16.47 (plus shipping) from Amazon.com (retail $24.95). |
| Guide to seasonal trading |
Sy Harding, editor of Street Smart Report, has just published Beat the Market the Easy Way -- an in-depth review of seasonal market patterns and their application to long-term timing. |
| Dick Davis Dividend |
In The Dick Davis Dividend, the investing legend shares a lifetime of insights on investing. |